Funding for this research was provided by:
Received: 15 May 2019
Accepted: 22 September 2019
First Online: 12 November 2019
Compliance with Ethical Standards
: Ethical approval for the study was obtained from the University of Sydney Human Research Ethics Committee (2014/054).
: Heidi N Beadnall has received honoraria for presentations and advisory boards and has received educational travel support from Novartis, whom markets Gilenya®. Michael Barnett has received institutional support for research, speaking and/or participation in advisory boards for Biogen, Merck, Novartis, Roche and Sanofi Genzyme. He is a research consultant at Medical Safety Systems and research director for the Sydney Neuroimaging Analysis Centre. Michael E Buckland has received honoraria for presentations from Novartis and Biogen.